FTH Faeth Therapeutics, Inc.

NASDAQ
$34.50

Faeth Therapeutics, Inc. (FTH) is expected to report earnings on November 3, 2026, during market hours. The consensus earnings estimate is a loss of $0.66 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +25.5% since its last earnings release on August 4, 2026.

Faeth Therapeutics Missed Consensus Estimates
Tuesday, August 4, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · 7:30 AM ET
Earnings Whisper
-
vs ($0.66)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $33.48

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Faeth Therapeutics, Inc.

Sensei Biotherapeutics Inc. is a clinical-stage immunotherapy company. It is focused on the discovery and development of therapeutics for cancer. The company's product pipeline includes SNS-301, SNS-401 and SNS-VISTA. Sensei Biotherapeutics Inc. is based in BOSTON, Md.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.